Viking Therapeutics (VKTX) Interest Coverage Ratio (2014 - 2026)
Viking Therapeutics (VKTX) posted Interest Coverage Ratio of 1.01 for Q2 2026, up 37.71% sequentially from 1.62 in Q1 2026, and down 3.98% YoY from 1.05 in Q2 2025.
Viking Therapeutics (VKTX) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Interest Coverage Ratio for 13 years, with the latest figure at 1.01 in Q2 2026.
- Quarterly Interest Coverage Ratio fell 3.98% year-over-year to 1.01 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 4.27 (down 53.87% YoY) and the FY2025 annual result came in at 3.45, down 275.17% from the prior year.
- Interest Coverage Ratio rose to 1.01 in Q2 2026 per VKTX's latest filing, from 1.62 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.0 in Q1 2023 and troughed at 9.84 in Q2 2022.
- A 5-year average of 2.08 and a median of 0.9 in 2025 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio soared 100.0% in 2023, then plunged 31826.29% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 0.99 in 2022, then surged by 52.39% to 0.47 in 2023, then soared by 40.14% to 0.28 in 2024, then tumbled by 412.86% to 1.45 in 2025, then grew by 29.96% to 1.01 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1.01, 1.62, and 1.45 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | -1.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.01 |
| Mar 31, 2026 | -1.63 |
| Dec 31, 2025 | -1.45 |
| Sep 30, 2025 | -1.31 |
| Jun 30, 2025 | -0.97 |
| Mar 31, 2025 | -0.84 |
| Dec 31, 2024 | -0.28 |
| Sep 30, 2024 | -0.14 |
| Jun 30, 2024 | -0.15 |
| Mar 31, 2024 | -0.08 |
| Dec 31, 2023 | -0.47 |
| Sep 30, 2023 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | -0.99 |
| Sep 30, 2022 | -9.19 |
| Jun 30, 2022 | -9.84 |
| Mar 31, 2022 | -9.07 |
| Dec 31, 2021 | -4.34 |
| Sep 30, 2021 | -2.41 |